UCB's bimekizumab shows early promise in psoriatic arthritis

11 June 2016

Belgian drugmaker UCB (Euronext Brussels: UCB) has shown fast and sustained efficacy with its psoriatic arthritis (PsA) candidate bimekizumab.

The Phase Ib study evaluated the pharmacokinetics, safety, tolerability and preliminary efficacy of multiple doses of bimekizumab in patients with PsA who had inadequate responses to at least one disease-modifying anti-rheumatic drug (DMARD), and/or one biologic.

Despite the limited patient set and exposure, the results have provided some excitement at the potential of bimekizumab, which is a highly selective monoclonal antibody that inhibits the activity of both IL-17A and IL-17F, key pro-inflammatory cytokines expressed in several inflammatory diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK